| Biotechnology Industry | Healthcare Sector | Junli He CEO | OTC PINK Exchange | 09074M202 CUSIP |
| US Country | 8 Employees | - Last Dividend | 22 Dec 2017 Last Split | - IPO Date |
Harvard Apparatus Regenerative Technology Inc., also known as HART, is a pioneering clinical-stage biotechnology company that has taken a focused approach towards developing regenerative medicine treatments specifically tailored for disorders of the gastrointestinal system, along with conditions affecting other organs due to cancer, trauma, or congenital defects. The company, which initiated its operations in 2009 and is based in Holliston, Massachusetts, rebranded from Biostage, Inc. to its current name in July 2023. The strategic vision of HART is centered on leveraging organ-regeneration technology to offer innovative solutions for the repair or replacement of diseased or damaged organs, thereby addressing a significant unmet medical need in the field of regenerative medicine.
The flagship product candidate of HART, the Cellspan Esophageal Implant, is at the forefront of addressing severe esophageal diseases. This groundbreaking technology is designed to cater to patients suffering from critical ailments affecting the esophagus, including but not limited to traumatic injuries, severe caustic burns, tissue damage resulting from aggressive chemoradiation therapy, congenital birth defects, and conditions necessitating the reconstruction of the esophageal tract. By harnessing the power of regenerative medicine, the Cellspan Implant offers a promising treatment alternative aimed at restoring normal function and improving the quality of life for patients afflicted with these complex esophageal conditions.
HART's pipeline is enriched with advanced organ-rejuvenation technologies dedicated to the repair or replacement of diseased or damage organs. The scope of these technologies encompasses a wide range of conditions, with the potential to revolutionize treatment approaches for multiple organs beyond the esophagus, including the colon and uterus. The aim is to provide therapeutic options for wound repair and reconstruction, thereby contributing to the field of regenerative medicine with solutions that promote healing, recovery, and the restoration of organ functionality in cases of trauma, cancer, or birth defects.
Aside from its clinical-stage endeavors, HART also proffers a line of Longevity products that underline its commitment to personal healthcare and wellness. This product range features longevity dietary supplements that are meticulously developed to support and enhance the overall health and well-being of individuals. Positioned at the intersection between advanced biotechnology and preventive healthcare, these supplements embody HART’s dedication to fostering longer, healthier lives through scientific innovation. By integrating cutting-edge research in regenerative medicine with practical applications in daily health maintenance, HART's Longevity products aim to empower individuals to take proactive steps towards sustaining their health and vitality.